Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1Alopecia 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoconjugates × 1 year × Clear all
NCT07474558 2026-03-16

SCARLET-ICE

Jules Bordet Institute

Phase 2 Not yet recruiting
102 enrolled

Alopecia

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Ambrx, Inc.

Phase 2 Active not recruiting
72 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡